{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:51:06Z","timestamp":1792014666348,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":391,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The sodium\u2013glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes at high cardiovascular risk or with CKD. Patients with type 2 diabetes commonly have coexisting HF or CKD that require treatment with loop diuretics; however, the prognostic implications of oral loop diuretic intensification are not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this participant-level pooled analysis of the CREDENCE and CANVAS trials (not including CANVAS-R), 1454\/8731 (16.7%) patients were treated with loop diuretics at baseline. Over a median on-treatment follow-up of 2.2\u2009years, 1264 patients (14.5%) required oral loop diuretic intensification, of whom 981 (77.6%) required initiation of oral loop diuretics and 283 (22.4%) required oral loop diuretic dose increase. Patients requiring oral loop diuretic intensification experienced rates of subsequent HF hospitalization, CKD progression and mortality that were 29.5-, 5.0-, and 3.5-fold higher, respectively, than those not requiring oral loop diuretic intensification. Treatment with canagliflozin reduced the need for oral loop diuretic intensification by 41% (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.53\u20130.66) including both new diuretic initiation (HR 0.65; 95% CI 0.57\u20130.74) and diuretic dose increase (HR 0.42; 95% CI 0.33\u20130.54). Inclusion of oral diuretic intensification in an expanded HF composite outcome inclusive of cardiovascular death and HF hospitalization approximately double the number of events, with similar observed treatment effect (HR 0.64; 95% CI 0.58\u20130.70).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among high-risk patients with type 2 diabetes, new oral loop diuretic intensification was frequent and portended adverse prognostic significance. Treatment with canagliflozin significantly reduced the need for loop diuretic intensification.<\/jats:p>\n                    <jats:p>Clinical Trial Registration: CANVAS (Canagliflozin Cardiovascular Assessment Study), ClinicalTrials.gov \u00a0NCT01032629; CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation), ClinicalTrials.gov \u00a0NCT02065791.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3586","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:39:25Z","timestamp":1737603565000},"page":"994-1002","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Canagliflozin Reduces Oral Loop Diuretic Intensification in Patients with Type 2 Diabetes: A Participant-Level Pooled Analysis of the CANVAS and CREDENCE Trials"],"prefix":"10.1093","volume":"27","author":[{"given":"Safia","family":"Chatur","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Pharmacy and Pharmacology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]},{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Pollock","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Sydney Medical School, University of Sydney , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research, Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]},{"name":"Department of Epidemiology and Biostatistics, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Jardine","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney , Sydney, NSW ,","place":["Australia"]},{"name":"Department of Renal Medicine, Concord General Repatriation Hospital , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]},{"name":"Department of Renal Medicine, Royal North Shore Hospital , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2026021721480684000_ejhf3586-bib-0001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721480684000_ejhf3586-bib-0002","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/dom.14386","article-title":"The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial","volume":"23","author":"Arnott","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026021721480684000_ejhf3586-bib-0003","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"key":"2026021721480684000_ejhf3586-bib-0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721480684000_ejhf3586-bib-0005","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"},{"key":"2026021721480684000_ejhf3586-bib-0006","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: A prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"2026021721480684000_ejhf3586-bib-0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: A post hoc analysis of the EMPEROR-Preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021721480684000_ejhf3586-bib-0008","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ejhf.2220","article-title":"Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA-REG OUTCOME trial","volume":"23","author":"Pellicori","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721480684000_ejhf3586-bib-0009","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: Diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026021721480684000_ejhf3586-bib-0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: Nomenclature, epidemiology, and future directions: JACC review topic of the week","volume":"81","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721480684000_ejhf3586-bib-0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021721480684000_ejhf3586-bib-0012","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721480684000_ejhf3586-bib-0013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/hr.2014.32","article-title":"Effects of prescribed antihypertensives and other cardiovascular drugs on mortality in patients with atrial fibrillation and hypertension: A cohort study from Sweden","volume":"37","author":"Carlsson","year":"2014","journal-title":"Hypertens Res"},{"key":"2026021721480684000_ejhf3586-bib-0014","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2026021721480684000_ejhf3586-bib-0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026021721480684000_ejhf3586-bib-0016","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021721480684000_ejhf3586-bib-0017","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721480684000_ejhf3586-bib-0018","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jchf.2020.10.002","article-title":"Standardized definitions for evaluation of heart failure therapies: Scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026021721480684000_ejhf3586-bib-0019","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721480684000_ejhf3586-bib-0020","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/6\/994\/66824994\/eurjhf_27_6_994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/6\/994\/66824994\/eurjhf_27_6_994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:48:13Z","timestamp":1771382893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/6\/994\/8468438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3586","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"2024-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}